News in Brief

Pediatric Group Warns About 'Smart Drugs'

Article Tools
  • PrintPrinter-Friendly
  • EmailEmail Article
  • ReprintReprints
  • CommentsComments

The American Academy of Neurology has officially weighed in against prescribing "smart drugs" to improve attention and cognition in healthy children.

Pediatric neurologists at the Yale School of Medicine wrote in a position statement in the journal Neurology this month that off-label prescriptions, particularly of stimulants such as Adderall and Ritalin, have risen in parallel with increasing diagnoses of attention deficit disorders.

The researchers found a nearly 22 percent increase in ADHD diagnoses in the past 20 years, including a 53 percent increase among Hispanic children.

Those increases raise troubling ethical and scientific problems, the researchers argue. The long-term health and safety of the drugs, known technically as nootropics, have not been thoroughly studied in children and adolescents, and the drugs may have very different effects on children, whose cognitive abilities are still in flux. Moreover, children and teenagers may be more susceptible to pressure from parents or peers to take the drugs in order to achieve academically, the researchers warned.

Vol. 32, Issue 26, Page 4

Published in Print: March 27, 2013, as Pediatric Group Warns About 'Smart Drugs'
Related Stories
Notice: We recently upgraded our comments. (Learn more here.) If you are logged in as a subscriber or registered user and already have a Display Name on, you can post comments. If you do not already have a Display Name, please create one here.
Ground Rules for Posting
We encourage lively debate, but please be respectful of others. Profanity and personal attacks are prohibited. By commenting, you are agreeing to abide by our user agreement.
All comments are public.

Back to Top Back to Top

Most Popular Stories